Unknown

Dataset Information

0

Afatinib induces pro-survival autophagy and increases sensitivity to apoptosis in stem-like HNSCC cells.


ABSTRACT: Afatinib, a second-generation tyrosine kinase inhibitor (TKI), exerts its antitumor effects in head and neck squamous cell carcinoma (HNSCC) by inducing intrinsic apoptosis through suppression of mTORC1. However, the detailed mechanism and biological significance of afatinib-induced autophagy in HNSCC remains unclear. In the present study, we demonstrated that afatinib induced mTORC1 suppression-mediated autophagy in HNSCC cells. Further mechanistic investigation revealed that afatinib stimulated REDD1-TSC1 signaling, giving rise to mTORC1 inactivation and subsequent autophagy. Moreover, ROS generation elicited by afatinib was responsible for the induction of the REDD1-TSC1-mTORC1 axis. In addition, pharmacological or genetic inhibition of autophagy sensitized HNSCC cells to afatinib-induced apoptosis, demonstrating that afatinib activated pro-survival autophagy in HNSCC cells. Importantly, in vitro and in vivo assays showed that afatinib caused enhanced apoptosis but weaker autophagy in stem-like HNSCC cells constructed by CDH1 knockdown. This suggested that blocking autophagy has the potential to serve as a promising strategy to target HNSCC stem cells. In conclusion, our findings suggested that the combination treatment with afatinib and autophagy inhibitors has the potential to eradicate HNSCC cells, especially cancer stem cells in clinical therapy.

SUBMITTER: Liu X 

PROVIDER: S-EPMC8298552 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC3824659 | biostudies-literature
| S-EPMC6613886 | biostudies-literature
| S-EPMC6819521 | biostudies-literature
2023-10-24 | PXD042004 | Pride
| S-EPMC3973232 | biostudies-literature
| S-EPMC4385843 | biostudies-literature
| S-EPMC7229259 | biostudies-literature
| S-EPMC8704163 | biostudies-literature
| S-EPMC4467405 | biostudies-literature
| S-EPMC8343999 | biostudies-literature